Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × fludarabine × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 14 Genitourinary 9 Gynecologic 7 Gastrointestinal 7 Breast 7 Thoracic 5 Tumor-Agnostic 3 Head & Neck 3 Plasma cell 2 Lymphoid 2 CNS 2 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Classical hematology 1

Conditions

Sarcoma, Synovial 8 Sarcoma 8 Osteosarcoma 8 Neoplasms 7 Melanoma 7 Liposarcoma, Myxoid 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neuroblastoma 6 Myelodysplastic Syndromes 6 Leukemia, Myeloid, Acute 6 Dendritic Cell Sarcoma, Interdigitating 6 Rhabdomyosarcoma 5 Multiple Myeloma 5 Lymphoma, Mantle-Cell 5 Lymphoma, B-Cell, Marginal Zone 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Hodgkin Disease 5 Burkitt Lymphoma 5 Sarcoma, Ewing 4 Ovarian Neoplasms 4 Lymphoma, Follicular 4 Leukemia, Prolymphocytic 4 Wilms Tumor 3 Triple Negative Breast Neoplasms 3 Rhabdoid Tumor 3 Lymphoma, T-Cell 3 Leukemia 3 Esophageal Neoplasms 3 Urinary Bladder Neoplasms 2

Interventions

pembrolizumab 8 Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 8 Cyclophosphamide 8 Specimen Handling 7 pazopanib 6 Biopsy 6 Radiosurgery 5 Nivolumab 5 Magnetic Resonance Spectroscopy 5 Imatinib Mesylate 5 Bevacizumab 5 regorafenib 4 Zoledronic Acid 4 Irinotecan 4 Docetaxel 4 Radiation 3 Ifosfamide 3 Cryosurgery 3 Carboplatin 3 trastuzumab deruxtecan 2 trametinib 2 temsirolimus 2 sargramostim 2 olaparib 2 masitinib 2 ganitumab 2 futibatinib 2 conatumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01343043 2021-06-30

NY-ESO-1

GlaxoSmithKline

Phase 1 Completed

50 enrolled 17 charts

Neoplasm Metastasis, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡